Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Garrido, Patrícia ^a,b   Ribeiro, Sandra ^c   Fernandes, João ^a,b   Vala, Helena ^d   Da Rocha, Elsa Bronze ^c   Rocha Pereira, Petronila ^e   Belo, Luís ^c   Costa, Elísio ^c   Santos Silva, Alice ^c   Reis, Flávio ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; ERYTHROPOIETIN; FERROPORTIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 2BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRON; TRANSFERRIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CELL DAMAGE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EPO GENE; GENE EXPRESSION; GLOMERULOPATHY; HORMONE BLOOD LEVEL; HYPOXIA; INTERSTITIAL NEPHRITIS; IRON ABSORPTION; IRON BLOOD LEVEL; IRON METABOLISM DISORDER; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY INJURY; LIVER LEVEL; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RAT; RAT MODEL; RENAL HYPOXIA; TRANSFERRIN BLOOD LEVEL; ANIMAL; BLOOD; DISEASE MODEL; FIBROSIS; GENETICS; INFLAMMATION; KIDNEY; LIVER; METABOLISM; ORGAN SIZE; SURGERY; WISTAR RAT;

RATTUS;

ANEMIA; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FIBROSIS; HEPCIDINS; INFLAMMATION; IRON; KIDNEY; LIVER; MALE; ORGAN SIZE; RATS; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER;

EID: 84929485374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124048     Document Type: Article

References (70)

1. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007; 13(3 Suppl): S1-S9. PMID: 17402808.
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162(12): 1401-1408. PMID: 12076240.
3. Weisbord SD, Kimmel PL. Health-related quality of life in the era of erythropoietin. Hemodial Int. 2008; 12(1): 6-15. doi:10.1111/j.1542-4758.2008.00233.x PMID: 18271834.
4. Liu J, Guo H, Gilbertson D, Foley R, Collins A. Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis. Ther Clin Risk Manag. 2009; 5(4): 319-330. PMID: 19753126.
5. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(1): 48-56. doi:10.2215/cjn.05301107PMID: 19056614.
6. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl. 2002;(80: ): 44-48. PMID: 11982812.
7. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: Here are we now and where do we go from here? Nephrol Dial Transplant. 2004; 19(2): 288-293. PMID: 14736947.
8. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int. 2005; 68 (5):2323-30. doi:10.1111/j.1523-1755.2005.00693.x PMID: 16221236.
9. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007; 18(12): 3164-3170. doi:10.1681/asn.2007010058 PMID: 18003781.
10. Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 2007; 30(1): 15-30. doi:10.1159/000098522PMID:17215586.
11. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol. 2010; 20 (3): 125-131. doi:10.4103/0971-4065.70840 PMID: 21072151.
12. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012. doi:10.1016/j.bbamcr.2012.01.014 PMID: 22306005.
13. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704): 2090- 2093. doi:10.1126/science.1104742 PMID: 15514116.
14. Beaumont C. Molecular mechanisms of iron homeostasis. Med Sci (Paris). 2004; 20(1): 68-72. doi:10.1051/medsci/200420168 PMID: 14770366.
15. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007; 117(7): 1926-1932. doi:10.1172/jci31370 PMID: 17557118.
16. Chepelev NL, Willmore WG. Regulation of iron pathways in response to hypoxia. Free Radic Biol Med. 2011; 50(6): 645-666. doi:10.1016/j.freeradbiomed.2010.12.023 PMID: 21185934.
17. Mimura I, Nangaku M. The suffocating kidney: Tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010; 6(11): 667-678. doi:10.1038/nrneph.2010.124 PMID: 20877304.
18. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant. 2011; 26(4): 1132-1137. doi:10.1093/ndt/gfq832 PMID: 21330358.
19. Hamada Y, Kono TN, Moriguchi Y, Higuchi M, Fukagawa M. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: A possible mechanism of iron deficiency in chronic kidney disease patients on treatment. Nephrol Dial Transplant. 2008; 23(6): 1886- 1891. doi:10.1093/ndt/gfm900 PMID: 18174266.
20. Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant. 2013; 28(7): 1733-1743. doi:10.1093/ndt/gfs584 PMID: 23345622.
21. Liu ZC, Chow KM, Chang TM. Evaluation of two protocols of uremic rat model: partial nephrectomy and infarction. Ren Fail. 2003; 25(6): 935-943. PMID: 14669852.
22. Garrido P, Reis F, Costa E, Teixeira-Lemos E, Parada B, Alves R, et al. Characterization of a rat model of moderate chronic renal failure-focus on hematological, biochemical, and cardio-renal profiles. Ren Fail. 2009; 31(9): 833-842. doi:10.3109/08860220903151435 PMID: 19925293.
23. Garrido P, Santos-Silva A, Reis F. Animal Models of Kidney Disease-associated Anemia. In: Costa Elísio, Reis Flávio and Santos-Silva Alice, editors. Frontiers in Drug Discovery, Erythropoietic Stimulating Agents; 2013. pp. 89-120.
24. Teixeira M, Rodrigues-Santos P, Garrido P, Costa E, Parada B, Sereno J, et al. Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. J Pharm Bioallied Sci. 2012; 4(1): 76-83. doi:10.4103/0975-7406.92743 PMID: 22368404.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402-408. doi:10.1006/meth.2001.1262 PMID: 11846609.
26. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003; 162(6): 1789-1806. doi:10.1016/s0002-9440(10)64314-3 PMID: 12759237.
27. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72(3): 247-259. doi:10.1038/sj.ki.5002343 PMID: 17568785.
28. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: Applications and implications. Am J Kidney Dis. 2009; 53(3 Suppl 3): S4-S16. doi:10.1053/j.ajkd.2008.07.048 PMID: 19231760.
29. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002; 136(8): 604-615. PMID: 11955029.
30. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004; 66(4): 1310-1314. doi:10.1111/j.1523-1755.2004.00894.x PMID: 15458424.
31. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal Biochem. 1996; 239(1): 70-76. doi:10.1006/abio.1996.0292 PMID: 8660627.
32. Fine L. The biology of renal hypertrophy. Kidney Int. 1986; 29(3): 619-634. PMID: 2422432.
33. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol. 1981; 241(1): F85-F93. PMID: 7246778.
34. Malt RA. Compensatory growth of the kidney. N Engl J Med. 1969; 280(26): 1446-1459. doi:10.1056/nejm196906262802606 PMID: 4240312.
35. Peters G. Introduction: History and problems of compensatory adaptation of renal functions and of compensatory hypertrophy of the kidney. Yale J Biol Med. 1978; 51(3): 235-245. PMID: 366923.
36. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci (Landmark Ed). 2009; 14: 2448-2465. PMID: 19273211.
37. Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The cardio-renal anaemia syndrome: Does it exist? Nephrol Dial Transplant. 2003; 18 Suppl 8: viii7-12. PMID: 14607993.
38. Wexler D, Silverberg D, Blum M, Sheps D, Keren G, Wollman Y, et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant. 2005; 20 Suppl 7: vii11-5. doi:10.1093/ndt/gfh1101 PMID: 16024826.
39. Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Castaneda O, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol. 2006; 17 (12 Suppl 3): S246-S249. doi:10.1681/asn.2006080921 PMID: 17130269.
40. Brenner BM, Anderson S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol. 1992; 19 Suppl 6: S1-7. PMID: 1382155.
41. Sviglerova J, Kuncova J, Nalos L, Tonar Z, Rajdl D, Stengl M. Cardiovascular parameters in rat model of chronic renal failure induced by subtotal nephrectomy. Physiol Res. 2010; 59 Suppl 1: S81-88. PMID: 20626224.
42. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013; 27(1): 41-53. doi:10.1016/j.blre.2012.12.003 PMID: 23291219.
43. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005; 35 Suppl 3: 13- 19. doi:10.1111/j.1365-2362.2005.01525.x PMID: 16281953.
44. Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 2012; 14(3): 238-246. doi:10.1016/j.micinf.2011.10.005 PMID: 22094132.
45. Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell. 2008; 133(2): 223-234. doi:10.1016/j.cell.2008.02.038 PMID: 18423195.
46. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology. 1991; 1(4): 337-346. PMID: 1820196.
47. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 1987; 262(25): 12059-12076. PMID: 3624248.
48. Egrie JC, Browne JK. Development and characterization of darbepoetin alfa. Oncology (Williston Park). 2002; 16(10 Suppl 11): 13-22. PMID: 12435169.
49. Higuchi M, Oh-eda M, Kuboniwa H, Tomonoh K, Shimonaka Y, Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem. 1992; 267(11): 7703-7709. PMID: 1560005.
50. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007; 435: 179-197. doi:10.1016/s0076-6879(07)35010-6 PMID: 17998055.
51. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010; 55(4): 726-741. doi:10.1053/j.ajkd.2009.12.030 PMID: 20189278.
52. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352(10): 1011-1023. doi:10.1056/NEJMra041809 PMID: 15758012.
53. Costa E, Rocha S, Rocha-Pereira P, Reis F, Castro E, Teixeira F, et al. DMT1 (NRAMP2/DCT1) genetic variability and resistance to recombinant human erythropoietin therapy in chronic kidney disease patients under haemodialysis. Acta Haematol. 2008; 120(1): 11-13. doi:10.1159/000149496 PMID: 18667808.
54. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2alpha, but not HIF- 1alpha, promotes iron absorption in mice. J Clin Invest. 2009; 119(5): 1159-1166. doi:10.1172/jci38499 PMID: 19352007;.
55. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle. 2008; 7(1): 28-32. PMID: 18212530.
56. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110(7): 1037-1044doi:10.1172/jci15686 PMID: 12370282.
57. Volke M, Gale DP, Maegdefrau U, Schley G, Klanke B, Bosserhoff AK, et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS One. 2009; 4(11):e7875. doi:10.1371/journal.pone.0007875 PMID: 19924283.
58. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun. 2007; 356(1): 312-317. doi:10.1016/j.bbrc.2007.02.137 PMID: 17349976.
59. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol. 1994; 4(8): 1598-1607. PMID: 8025233.
60. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis. 1992; 20(6): 580-584. PMID: 1462986.
61. Harris DC, Tay C, Nankivell BJ. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol. 1994; 21(2): 73-81. PMID: 8039274.
62. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005; 16(12): 3631-3641. doi:10.1681/asn.2005050522 PMID: 16236804.
63. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Eguchi A, et al. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens. 2012; 30(11): 2192-2201. doi:10.1097/HJH.0b013e3283581a64 PMID: 22922699.
64. Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int. 1989; 36(5): 753-759. PMID: 2615188.
65. Remuzzi A, Puntorieri S, Brugnetti B, Bertani T, Remuzzi G. Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int. 1991; 39(4): 647-652. PMID: 2051721.
66. Rodriguez-Iturbe B, Garcia Garcia G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract. 2010; 116(2): c81-c88. doi:10.1159/000314656 PMID: 20502043.
67. Palm F, Nordquist L. Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. Clin Exp Pharmacol Physiol. 2011; 38(7): 474-480. doi:10.1111/j.1440-1681.2011.05532.x PMID: 21545630.
68. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol. 2004; 15(5): 1277-1288. PMID: 15100368.
69. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007; 117(12): 3810-3820. doi:10.1172/jci30487 PMID: 18037992.
70. Kroening S, Neubauer E, Wessel J, Wiesener M, Goppelt-Struebe M. Hypoxia interferes with connective tissue growth factor (CTGF) gene expression in human proximal tubular cell lines. Nephrol Dial Transplant. 2009; 24(11): 3319-3325doi:10.1093/ndt/gfp305 PMID: 19549692.